|
|
Volumn 1, Issue 6 SUPPL., 2002, Pages
|
|
Critical assessment of angiogenesis inhibitors in clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID;
3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE;
ANGIOGENESIS INHIBITOR;
ANGIOGENIC FACTOR;
ANGIOSTATIN;
ANTINEOPLASTIC AGENT;
BASIC FIBROBLAST GROWTH FACTOR;
BEVACIZUMAB;
CILENGITIDE;
COMBRETASTATIN A4;
CYTOTOXIC AGENT;
ENDOSTATIN;
FUMAGILLOL CHLOROACETYLCARBAMATE;
INTEGRIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY LM 609;
PLATELET DERIVED GROWTH FACTOR;
PROTEIN;
PROTEIN TYROSINE KINASE;
PROTEIN TYROSINE KINASE INHIBITOR;
SEMAXANIB;
THALIDOMIDE;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN;
VASCULOTROPIN ANTIBODY;
VASCULOTROPIN RECEPTOR;
VASCULOTROPIN RECEPTOR 2;
VATALANIB;
ANGIOGENESIS;
CLINICAL TRIAL;
CONFERENCE PAPER;
DRUG ACTIVITY;
DRUG INDUCED DISEASE;
DRUG TOLERABILITY;
ENDOTHELIUM CELL;
HUMAN;
HYPERTENSION;
MALIGNANT NEOPLASTIC DISEASE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
SIDE EFFECT;
THROMBOEMBOLISM;
|
|
EID: 0036836701
PISSN: 03008916
EISSN: None
Source Type: Journal
DOI: 10.1177/03008916020016s104 Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (4)
|
